Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × lazertinib × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 19 Observational 3 Expanded_access 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 1

Interventions

3-Iodobenzylguanidine 9 Magnetic Resonance Spectroscopy 5 Cyclophosphamide 5 Amifampridine 5 pembrolizumab 4 nilotinib 4 gallium 68 PSMA-11 4 fludarabine 4 elotuzumab 4 dabrafenib 4 Nivolumab 4 Afatinib 4 trametinib 3 midostaurin 3 fludarabine phosphate 3 Ipilimumab 3 Everolimus 3 Bortezomib 3 venetoclax 2 veliparib 2 tucatinib 2 tempol 2 talimogene laherparepvec 2 selinexor 2 ruxolitinib 2 regorafenib 2 pomalidomide 2 olaparib 2 nirogacestat 2 niraparib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Yuhan Corporation

Approved for marketing

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡